TY - JOUR
T1 - Heparin, klotho, and FGF23
T2 - the 3-beat waltz of the discordant heart
AU - Martinez-Calle, Marta
AU - David, Valentin
N1 - Funding Information:
VD received research funding from Akebia Therapeutics and Vifor Pharma and consulting honoraria from Keryx Biopharmaceuticals, Vifor Pharma, Luitpold, and Amgen (outside the submitted work). The other author declared no competing interests.
Funding Information:
VD was supported by grants from the National Institutes of Health (grant nos. R01DK102815 and R01DK114158 ).
Publisher Copyright:
© 2022 International Society of Nephrology
PY - 2022/8
Y1 - 2022/8
N2 - Excess fibroblast growth factor (FGF) 23 signaling in patients with chronic kidney disease induces left ventricular hypertrophy. In this issue, Yanucil et al. investigated the interaction of soluble klotho and heparin with FGF23 and FGF receptor isoforms. They concluded that heparin promotes the FGF23–FGF receptor isoform 4 interaction and FGF23 pathogenic effects, supporting an important role of heparin in the pathogenesis of FGF23-mediated left ventricular hypertrophy in chronic kidney disease.
AB - Excess fibroblast growth factor (FGF) 23 signaling in patients with chronic kidney disease induces left ventricular hypertrophy. In this issue, Yanucil et al. investigated the interaction of soluble klotho and heparin with FGF23 and FGF receptor isoforms. They concluded that heparin promotes the FGF23–FGF receptor isoform 4 interaction and FGF23 pathogenic effects, supporting an important role of heparin in the pathogenesis of FGF23-mediated left ventricular hypertrophy in chronic kidney disease.
UR - http://www.scopus.com/inward/record.url?scp=85134532973&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134532973&partnerID=8YFLogxK
U2 - 10.1016/j.kint.2022.05.009
DO - 10.1016/j.kint.2022.05.009
M3 - Comment/debate
C2 - 35870810
AN - SCOPUS:85134532973
SN - 0085-2538
VL - 102
SP - 228
EP - 230
JO - Kidney International
JF - Kidney International
IS - 2
ER -